Pioneer Investment Management Inc. increased its position in shares of Shire PLC (NASDAQ:SHPG) by 331.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 67,699 shares of the biopharmaceutical company’s stock after buying an additional 52,000 shares during the period. Pioneer Investment Management Inc.’s holdings in Shire PLC were worth $11,189,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in SHPG. Pictet Asset Management Ltd. increased its position in Shire PLC by 10.3% in the second quarter. Pictet Asset Management Ltd. now owns 455,908 shares of the biopharmaceutical company’s stock worth $78,744,000 after buying an additional 42,466 shares during the period. Goelzer Investment Management Inc. increased its position in Shire PLC by 1.6% in the second quarter. Goelzer Investment Management Inc. now owns 22,534 shares of the biopharmaceutical company’s stock worth $3,724,000 after buying an additional 351 shares during the period. Hartford Financial Management Inc. increased its position in Shire PLC by 5.4% in the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 32 shares during the period. Ingalls & Snyder LLC increased its position in Shire PLC by 10.8% in the second quarter. Ingalls & Snyder LLC now owns 1,284 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 125 shares during the period. Finally, Lockheed Martin Investment Management Co. increased its position in Shire PLC by 19.0% in the second quarter. Lockheed Martin Investment Management Co. now owns 35,700 shares of the biopharmaceutical company’s stock worth $5,900,000 after buying an additional 5,700 shares during the period. Institutional investors and hedge funds own 21.04% of the company’s stock.

Shares of Shire PLC (NASDAQ:SHPG) opened at 148.61 on Friday. Shire PLC has a 12-month low of $147.79 and a 12-month high of $209.22.

Shire PLC (NASDAQ:SHPG) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.53 by $0.20. Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. The company had revenue of $3.75 billion for the quarter. During the same quarter in the prior year, the business posted $3.38 EPS. The company’s revenue for the quarter was up 54.2% compared to the same quarter last year. Analysts anticipate that Shire PLC will post $14.93 EPS for the current year.

The business also recently announced a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be issued a $0.1527 dividend. This represents a yield of 0.21%. The ex-dividend date of this dividend is Thursday, September 7th. Shire PLC’s dividend payout ratio is currently 40.63%.

ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.dailypolitical.com/2017/08/12/pioneer-investment-management-inc-has-11-19-million-position-in-shire-plc-shpg.html.

A number of equities analysts have issued reports on the company. Barclays PLC downgraded Shire PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday. Jefferies Group LLC reiterated a “hold” rating and set a $206.00 price target (down previously from $216.00) on shares of Shire PLC in a research note on Wednesday. Zacks Investment Research upgraded Shire PLC from a “sell” rating to a “hold” rating in a research note on Tuesday. BidaskClub downgraded Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. Finally, Royal Bank Of Canada set a $213.00 price target on Shire PLC and gave the company a “buy” rating in a research note on Friday, August 4th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the stock. Shire PLC has a consensus rating of “Buy” and an average target price of $222.27.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.